Janssen-Cilag Guselkumab receives UK nod for Crohn's disease, ulcerative colitis Ruchika Sharma20 May 2025 2:45 PM ISTJanssen-Cilag Limited has received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) for guselkumab (Tremfya) to treat...
USFDA nod to JnJ Tremfya for Crohn's disease Ruchika Sharma21 March 2025 10:30 AM ISTHorsham: Johnson & Johnson has announced that the Company ahs received approval from the U.S. Food and Drug Administration (FDA) for TREMFYA...
JnJ seeks USFDA nod for Tremfya for treatment of plaque psoriasis, juvenile psoriatic arthritis in children Ruchika Sharma3 Dec 2024 12:30 PM ISTSpring House: Johnson & Johnson has announced the submission of two supplemental Biologics License Applications (sBLAs) to the U.S. Food and...
JnJ seeks USFDA approval for subcutaneous induction regimen of Tremfya in ulcerative colitis Ruchika Sharma29 Nov 2024 11:30 AM ISTSpring House: Johnson & Johnson has announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug...
JnJ Tremfya receives USFDA approval for adults with moderately to severely active ulcerative colitis Ruchika Sharma12 Sept 2024 12:30 PM ISTHorsham: Johnson & Johnson has announced that the U.S. Food and Drug Administration (FDA) has approved TREMFYA (guselkumab) for the treatment of...
JnJ seeks USFDA approval for Tremfya for moderately to severely active Crohn's disease Ruchika Sharma22 Jun 2024 2:21 PM ISTSpring House: Johnson & Johnson has announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug...
JnJ submits regulatory applications to EMA for Tremfya for treatment of patients with ulcerative colitis, Crohn's disease Ruchika Sharma5 May 2024 1:30 PM ISTBeerse: Janssen-Cilag International NV, a Johnson & Johnson company, has announced it has submitted applications to the European Medicines...
Johnson & Johnson seeks USFDA nod for Tremfya for ulcerative colitis treatment in adults Ruchika Sharma12 March 2024 12:39 PM ISTSpring House: Johnson & Johnson has announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug...
Guselkumab efficacious among patients of psoriasis with skin of color Dr. Kamal Kant Kohli24 Oct 2023 10:15 AM ISTUSA: Guselkumab exhibited fast and significant clearance in body and scalp psoriasis after one dose in patients with skin of color in a phase 3b...
